Why Bruce Willis doesn't know he has dementia? Here's what frontotemporal disease does to the brain
Bruce Willis had retired from acting in 2022 after being diagnosed with aphasia. It is the inability to formulate language due to damage to areas of the brain. It was announced the following year that the Hollywood star had been diagnosed with frontotemporal dementia. It is one of the most common forms of dementia in people under 60.
Read full articleMORE NEWS
$57.2 billion Treasury cash drain hits Wall Street this week: Why semiconductor stocks and SMH ETF investors face more volatility, with a bigger liquidity test coming in 2027
Upcoming Treasury bill settlements on November 10 and 12 are expected to withdraw $57.2 billion from markets. The VanEck Semiconductor ETF has already experienced a notable decline since October, losing nearly 25 percent of its value. Historical trading data indicates that semiconductor stocks perform better when Treasury bill issuance is lower. A potential easing of liquidity pressure may occur in December due to reduced auction sizes.
Between the chip and the slip: Honeytrap suspicions further sours ties between US and China
Nvidia's CEO Jensen Huang is being investigated for having an alleged affair with a potential Chinese intelligence agent. This individual reportedly sought to gather information about Nvidia's advanced technology. Nvidia's board has launched an independent probe to examine the allegations against Huang. US lawmakers are demanding a briefing on the matter amid heightened concerns over national security.
Russia-Ukraine peace talks: In Abu Dhabi, US to look for security guarantees for both
The talks follow last month's localized truce around the Russian-occupied city of Oleshky in southern Ukraine that was brokered with the help of US first lady Melania Trump and allowed the evacuation of some of its residents and the delivery of desperately needed humanitarian supplies.
Ozempic Zepbound eye risk warnings: Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDA
Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (US FDA).
